Compound ID | 129
Class: Glycopeptide
| Spectrum of activity: | Gram-positive |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus sp. |
| Propensity to select resistant mutants: | Yes |
| Institute where first reported: | Cooper Group, University of Queensland, Australia |
| Year first mentioned: | unknown |
| Highest development stage: | Preclinical |
| Development status: | Experimental |